1,195
Views
1
CrossRef citations to date
0
Altmetric
Article; Medical Biotechnology

Construction of COX-2 short hairpin RNA expression vector and its inhibitory effect on hepatic fibrosis

, , , , , , & show all
Pages 653-662 | Received 07 Mar 2017, Accepted 19 Jan 2018, Published online: 30 Jan 2018

References

  • Motino O, Agra N, Brea Contreras R, et al. Cyclooxygenase-2 expression in hepatocytes attenuates non- alcoholic steatohepatitis and liver fibrosis in mice. Biochim Biophys Acta. 2016;1862:1710–1723.
  • Chang HK, Chang EY, Ryu S, et al. Cyclooxygenase-2 inhibitor reduces hepatic stiffness in pediatric chronic liver disease patients following kasai portoenterostomy. Yonsei Med J. 2016;57:893–899.
  • Kim J, Lee J, Shin CM, et al. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care. 2015;3:e000133.
  • Nie QH, Zhu CL, Zhang YF, et al. Inhibitory effect of antisense oligonucleotide targeting timp-2 on immune-induced liver fibrosis. Dig Dis Sci. 2010;55:1286–1295.
  • Robinson PM, Blalock TD, Yuan R, et al. Hammerhead ribozyme-mediated knockdown of mRNA for fibrotic growth factors: transforming growth factor-beta 1 and connective tissue growth factor. Methods Mol Biol. 2012;820:117–132.
  • Gonzalez-Rodriguez A, Valverde AM. RNA interference as a therapeutic strategy for the treatment of liver diseases. Curr Pharm Des. 2015;21:4574–4586.
  • Lam JK, Chow MY, Zhang Y, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
  • Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014;538:217–227.
  • Presloid JB, Novella IS. RNA viruses and RNAi: quasispecies implications for viral escape. Viruses. 2015;7:3226–3240.
  • Kola VS, Renuka P, Madhav MS, et al. Key enzymes and proteins of crop insects as candidate for rnai based gene silencing. Front Physiol. 2015;6:119.
  • Mansoori B, Sandoghchian Shotor-bani S, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull. 2014;4:313–321.
  • Dyawanapelly S, Ghodke SB, Vishwanathan R, et al. RNA interference-based therapeutics: molecular platforms for infectious diseases. J Biomed Nanotechnol. 2014;10:1998–2037.
  • Sioud M. RNA interference: mechanisms, technical challenges, and therapeutic opportunities. Methods Mol Biol. 2015;1218:1–15.
  • Ipsaro JJ, Joshua-Tor L. From guide to target: molecular insights into eukaryotic RNA-interference machinery. Nat Struct Mol Biol. 2015;22:20–28.
  • Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. 2014;22:692–701.
  • Holen T, Amarzguioui M, Wiiger MT, et al. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. 2002;30:1757–1766.
  • Yamada T, Peng CG, Matsuda S, et al. Versatile site-specific conjugation of small molecules to siRNA using click chemistry. J Org Chem. 2011;76:1198–1211.
  • El-Sagheer AH, Brown T. New strategy for the synthesis of chemically modified RNA constructs exemplified by hairpin and hammerhead ribozymes. Proc Natl Acad Sci USA. 2010;107:15329–15334.
  • Li G, Li XP, Jiang L, et al. [Silencing of cox-2 in nasopharyngeal carcinoma cells with a shRNAmir lentivirus vector]. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29:1111–1114. Chinese.
  • Yu Y, Zhang S, Kong W. [Construction and identification of eukaryotic plasmid pGC-silencer-U6/Neo/GFP/ABCG2]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24:795–798. Chinese.
  • Zhang MX, Wu J, Xin M, et al. Construction and identification of eukaryotic expression plasmid expressing siRNA targeting Rac1 and detection of its specific downregulation effect. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40:969–972.
  • Zhou X, Yang XF. Progress of targeting transforming growth factor-β1 small interfering RNA in liver fibrosis. Chin Med Sci J. 2014;29(4):231–235.
  • Dow LE, Premsrirut PK, Zuber J, et al. A pipeline for the generation of shRNA transgenic mice. Nat Protoc. 2012;7:374–393.
  • Coward WR, Watts K, Feghali-Bostwick CA, et al. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol. 2009;29:4325–4339.
  • Pang L, Nie M, Corbett L, et al. Protein kinase C-ϵ mediates bradykinin-induced cyclooxygenase-2 expression in human airway smooth muscle cells. FASEB J. 2002;16:1435–1437.